EU GMP Annex 1 Review India - 1-Year Update

The revised EU GMP Annex 1: Manufacture of Sterile Medicinal Products represented a major change in how pharmaceutical companies approach sterility assurance. Published in August 2022, the revised Annex 1 became operational on 25 August 2023, with the exception of point 8.123, which had a later implementation date of 25 August 2024.

For Indian pharmaceutical manufacturers supplying medicines to Europe and other highly regulated markets, the change has been particularly significant. Annex 1 has pushed manufacturers beyond a checklist-based compliance model toward a more integrated, risk-based approach to contamination prevention.

The keyword EU GMP Annex 1 review India therefore goes beyond asking whether Indian sites have updated their SOPs. The more important question is: How have Indian sterile manufacturers changed their facilities, processes, monitoring systems and quality strategies after the revised requirements came into force?

This one-year review examines the major areas of adaptation, including Contamination Control Strategy (CCS), cleanroom design, barrier technologies, environmental monitoring, aseptic process simulation, personnel practices, data integrity and inspection readiness.

What Changed With the Revised EU GMP Annex 1?

The revised Annex 1 substantially expanded the expectations surrounding sterile manufacturing. Its central philosophy is prevention: contamination should be designed out and controlled throughout the manufacturing process rather than relying primarily on finished-product testing.

One of the most important requirements is the implementation of a Contamination Control Strategy (CCS) covering the facility and manufacturing process. The strategy should identify critical control points and assess the effectiveness of technical, procedural and organizational controls.

For Indian manufacturers, this has changed the way QA, production, engineering, microbiology and validation teams work together.

1. CCS Has Become the Foundation of Sterility Assurance

The most visible change following Annex 1 implementation has been the rise of the Contamination Control Strategy as a central quality document.

A mature CCS should connect:

• Facility and cleanroom design
• HVAC and airflow
• Personnel practices
• Utilities
• Raw materials
• Primary packaging components
• Equipment
• Cleaning and disinfection
• Sterilization
• Environmental monitoring
• Process monitoring
• Validation
• Maintenance
• Deviations and CAPA

The objective is not simply to create another controlled document. The CCS needs to demonstrate that contamination risks are understood and controlled across the entire operation.

How Indian manufacturers are adapting

Many sites have moved from individual risk assessments toward a more integrated contamination-control model. Existing procedures are increasingly mapped into a central CCS so that gaps can be identified and controls can be linked to specific risks.

This is particularly important for Indian manufacturers exporting to Europe, where inspection readiness increasingly depends on demonstrating how controls work together rather than presenting isolated validation reports.

2. Cleanroom Design Is Receiving Greater Attention

Annex 1 places strong emphasis on facility and process design as the first line of contamination control.

Indian manufacturers are therefore reviewing:

• Personnel and material flows
• Airflow patterns
• Pressure cascades
• Room classifications
• Equipment placement
• Cleanroom zoning
• Transfer systems
• Cleaning accessibility

The underlying principle is straightforward: good design should prevent contamination rather than depend entirely on monitoring to detect it.

This is consistent with Annex 1's emphasis on Quality Risk Management (QRM), where facility, equipment and process design should be prioritized before relying on monitoring systems as evidence of control.

3. Isolators and RABS Are Gaining Greater Importance

Barrier technologies have become increasingly important in Indian sterile manufacturing.

Manufacturers are evaluating or expanding the use of:

• Closed isolators
• Open isolators
• Restricted Access Barrier Systems (RABS)
• Glove-port systems
• Automated transfer systems

The reason is simple: reducing direct operator intervention can reduce opportunities for contamination.

For high-risk aseptic operations, isolators can provide a significantly more controlled environment than conventional open processing. However, implementation requires more than installing the equipment. Glove integrity, decontamination, transfer systems, airflow, pressure control and intervention strategies must all be incorporated into the CCS.

4. Environmental Monitoring Is Becoming More Risk-Based

Another major area of adaptation is environmental monitoring.

The revised Annex 1 provides more detailed expectations for monitoring viable and non-viable contamination. Indian manufacturers are increasingly reviewing sampling locations and frequencies using risk-based approaches instead of relying exclusively on historical sampling plans.

Modern sterile facilities are increasingly using:

• Continuous particle monitoring
• Portable particle counters
• Active microbial air samplers
• Settle plates
• Contact plates
• Personnel monitoring
• Automated data collection

The objective is not simply to collect more data. Monitoring should demonstrate that the facility remains under control and should provide meaningful information for trending and investigation.

5. Particle Monitoring Is Becoming More Sophisticated

Non-viable particle monitoring has become a critical component of contamination control.

Manufacturers are increasingly assessing whether particle monitoring locations adequately represent critical processing zones.

For Grade A areas, continuous monitoring can provide greater visibility into transient events during aseptic operations.

This is particularly relevant for:

• Aseptic filling
• Lyophilizer loading
• Open-vial handling
• Sterile connections
• Critical interventions

Online particle counters and automated monitoring platforms can also reduce manual transcription and improve data availability.

6. Glove Integrity Has Received Greater Attention

Where isolators or RABS are used, gloves are critical barrier components.

Indian manufacturers are strengthening programs for:

• Glove integrity testing
• Glove replacement
• Glove lifecycle assessment
• Visual inspection
• Post-maintenance testing
• Decontamination impact assessment

Automated Glove Integrity Testers can provide more standardized results than visual inspection alone.

The frequency of testing should be scientifically justified and integrated into the facility's contamination-control strategy.

7. Aseptic Process Simulation Is Being Reassessed

Media fills, formally known as Aseptic Process Simulation (APS), remain a critical verification tool.

Following Annex 1 implementation, manufacturers are paying greater attention to whether APS genuinely represents routine manufacturing.

This includes challenging:

• Normal interventions
• Worst-case interventions
• Operator activities
• Shift changes
• Equipment stoppages
• Material transfers
• Aseptic connections
• Extended processing periods

A media fill should demonstrate the effectiveness of the complete aseptic process rather than simply satisfy a scheduled validation exercise.

8. Personnel Behavior Remains a Major Focus

Technology cannot eliminate the risks associated with human intervention.

Consequently, Indian manufacturers are increasing emphasis on:

• Aseptic technique
• Gowning qualification
• Cleanroom behavior
• Intervention practices
• Personnel monitoring
• Periodic retraining

Training programs are increasingly being connected to contamination-control risks identified through the CCS.

This represents an important cultural shift: operators are not merely trained to follow procedures; they need to understand why each behavior matters.

9. Cleaning and Disinfection Strategies Are Being Strengthened

Annex 1 has also increased attention on cleaning and disinfection programs.

Manufacturers are reassessing:

• Disinfectant selection
• Rotation strategies
• Contact times
• Application methods
• Sporicidal coverage
• Disinfectant effectiveness
• Environmental monitoring trends

The effectiveness of the overall program should be supported by appropriate validation and microbiological evidence.

For Indian facilities operating large sterile manufacturing campuses, this can require coordination across production areas, warehouses, laboratories and support spaces.

10. Sterile Components and Primary Packaging Are Under Greater Scrutiny

Contamination control does not stop at the cleanroom door.

Manufacturers are reviewing the risks associated with:

• Vials
• Ampoules
• Syringes
• Elastomeric closures
• Single-use systems
• Tubing
• Sterile filters
• Transfer bags

Supplier qualification and incoming component controls have consequently become more closely linked to the CCS.

Recent industry commentary specifically highlights that, for Indian sterile injectable manufacturers, the practical implications of Annex 1 for elastomeric closures and primary packaging may become increasingly visible during inspection-readiness activities and regulatory inspections.

11. Container Closure Integrity Is Becoming More Important

For sterile injectable products, maintaining container closure integrity is essential to protecting the product after filling.

Manufacturers are therefore giving greater attention to:

• Container closure system design
• Component qualification
• Closure integrity
• Transport risks
• Container closure integrity testing (CCIT)
• Stability-related integrity considerations

Deterministic CCIT technologies can provide quantitative evidence of package integrity and complement the broader sterility assurance strategy.

12. Data Integrity Is Now Closely Connected to Contamination Control

The digitalization of environmental monitoring and automated equipment has created another important requirement: trustworthy data.

Indian manufacturers are increasingly evaluating:

• Audit trails
• User access controls
• Electronic signatures
• Time-stamped records
• Data backup
• System validation
• Cybersecurity
• Electronic review processes

This is particularly relevant when particle counters, environmental monitoring systems, glove testers and other connected equipment generate GMP records.

The goal is to ensure that contamination-control decisions are based on complete, accurate and attributable data.

13. Inspection Readiness Has Changed

Perhaps the most important lesson from the first year is that having an Annex 1 document is not the same as demonstrating effective Annex 1 implementation.

Industry experience following implementation shows that manufacturers have been at different stages: some completed gap assessments and remediation programs, while others were still determining how the revised requirements affected their facilities and processes.

For Indian sites, inspection readiness increasingly means being able to explain:

1. What the contamination risks are.
2. Which controls address those risks.
3. Why the controls are appropriate.
4. How their effectiveness is demonstrated.
5. What the monitoring data show.
6. How deviations are investigated.
7. How the CCS is continuously improved.

This requires alignment between QA, engineering, microbiology, validation and production.

14. Indian Manufacturers Are Moving From Gap Closure to Continuous Improvement

The first phase of Annex 1 implementation was largely about identifying gaps and closing them.

The next phase is more mature.

Manufacturers need to demonstrate that the CCS remains effective as:

• Equipment changes
• Processes change
• New products are introduced
• Facilities are modified
• New monitoring data become available
• Deviations occur
• Regulatory expectations evolve

The revised Annex 1 explicitly expects the CCS to be actively reviewed and updated where appropriate, with effectiveness considered as part of management review.

What Does the One-Year Review Tell Indian Pharma?

The biggest takeaway is that Annex 1 compliance is not a one-time project.

The transition can be viewed in three stages:

Stage 1: Gap Assessment

Manufacturers compare existing practices with the revised requirements.

Stage 2: Remediation

Facilities implement technical, procedural and organizational improvements.

Stage 3: Sustained Control

Manufacturers use monitoring, trending, QRM and management review to demonstrate that contamination controls remain effective.

The third stage is where long-term compliance will ultimately be determined.

Practical Annex 1 Checklist for Indian Manufacturers

Indian sterile manufacturers should periodically evaluate whether they have:

• A current, site-specific CCS
• Documented contamination risk assessments
• Qualified cleanrooms and clean-air equipment
• Appropriate barrier technology
• Validated cleaning and disinfection processes
• Risk-based environmental monitoring
• Robust particle monitoring
• Effective glove integrity testing
• Representative APS/media fills
• Qualified personnel
• Appropriate component controls
• Validated sterilization processes
• Container closure integrity controls
• Data-integrity-compliant electronic systems
• Effective deviation and CAPA processes
• Management review of CCS effectiveness

This checklist should be treated as a starting point rather than a substitute for a detailed regulatory assessment.

The Outlook for Indian Sterile Manufacturers

The revised Annex 1 is increasingly influencing facility investments and technology decisions in India.

Manufacturers serving highly regulated markets are likely to continue investing in:

• Isolator technology
• RABS
• Continuous environmental monitoring
• Automated particle counters
• Automated glove integrity testing
• Advanced decontamination systems
• Digital quality platforms
• Deterministic CCIT
• Automated aseptic filling

The commercial impact is also important. Strong contamination-control capabilities can help Indian manufacturers demonstrate reliability to international customers and strengthen their position in contract manufacturing and global supply chains.

At the same time, the March 2026 non-compliance statements involving Indian sites demonstrate that regulatory risk remains real. For example, the European GMP database records a serious GMP non-compliance statement following a March 2026 inspection of Swiss Parenterals sites in Ahmedabad.

This does not mean the cited issue was necessarily caused by Annex 1 deficiencies; rather, it illustrates why inspection readiness and sustained GMP compliance remain essential.

Conclusion

The first year of revised EU GMP Annex 1 implementation has fundamentally changed the conversation around sterile pharmaceutical manufacturing in India.

The shift is from simply demonstrating that a cleanroom meets specifications toward demonstrating that the entire contamination-control system works together.

For Indian manufacturers, the most important adaptations include stronger Contamination Control Strategies, greater use of barrier technologies, risk-based environmental monitoring, improved glove integrity programs, more representative aseptic process simulations, stronger component controls and greater emphasis on data integrity.

The next stage will be even more important. Manufacturers must demonstrate that these systems remain effective over time and that quality teams use real operational data to drive continuous improvement.

For companies targeting European and other highly regulated markets, EU GMP Annex 1 review India should therefore be viewed not merely as a compliance topic, but as an ongoing framework for improving sterility assurance, operational robustness and global competitiveness.